Skip to main content
  1. Market Insights
  2. Health
  3. Pharmaceuticals

Vaccines - Papua New Guinea

Papua New Guinea
  • The Vaccines market in Papua New Guinea is expected to witness significant growth in the coming years.
  • According to projections, the revenue in this market is estimated to reach US$6.85m in 2024.
  • Furthermore, it is anticipated that the market will experience a steady annual growth rate of -3.56% from 2024 to 2029.
  • As a result, the market volume is projected to reach US$5.71m by 2029.
  • In terms of global comparison, United States is expected to generate the highest revenue in the Vaccines market, with an estimated value of US$29.12bn in 2024.
  • Papua New Guinea is experiencing a growing demand for vaccines due to its unique geographical challenges and high prevalence of infectious diseases.

Definition:
This market covers vaccines against infectious diseases. They help to prevent diseases, usually through active immunization. Vaccines against infectious diseases transmitted by viruses (e.g., hepatitis A and B or COVID-19) and bacteria (e.g., typhoid fever or meningococcus) are included.

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: Pfizer, GlaxoSmithKline, Merck & Co, Sanofi, Moderna, AstraZeneca

In-Scope

  • Vaccines against infectious diseases
  • Prophylactic and therapeutic vaccines
  • Flu vaccines
  • COVID-19 vaccines

Out-Of-Scope

  • Sera and gammaglobulins
  • Antivirals
  • Antibiotics
Vaccines: market data & analysis - Cover

Market Insights report

Vaccines: market data & analysis

Study Details

    Revenue

    Notes: Data shown is using current exchange rates and reflects market impacts of the Russia-Ukraine war.

    Most recent update: Jun 2024

    Source: Statista Market Insights

    Notes: The chart “Comparable Estimates” shows the forecasted development of the selected market from different sources. Please see the additional information for methodology and publication date.

    Most recent update: Mar 2024

    Analyst Opinion

    Papua New Guinea, the largest country in the Pacific region, is home to a diverse population with over 800 languages spoken. While the country has made significant progress in reducing infant mortality rates, access to healthcare remains a challenge in many parts of the country. The Vaccines market in Papua New Guinea is developing slowly due to various factors.

    Customer preferences:
    There is a growing awareness among the population about the importance of vaccines in preventing diseases. However, traditional beliefs and practices continue to influence customer preferences in some parts of the country. Additionally, the high cost of vaccines and the lack of access to healthcare facilities are major barriers to the adoption of vaccines in the country.

    Trends in the market:
    The Vaccines market in Papua New Guinea is witnessing a slow but steady growth due to the increasing government focus on improving healthcare infrastructure. The government has launched several initiatives to increase vaccination coverage in the country, especially in rural areas. The private sector is also playing a significant role in expanding the availability of vaccines in the country.

    Local special circumstances:
    Papua New Guinea has a challenging geography with many remote and inaccessible areas, making it difficult to deliver vaccines to all parts of the country. The country also faces several health challenges, including a high burden of infectious diseases such as tuberculosis, malaria, and HIV/AIDS. These factors have a significant impact on the demand for vaccines in the country.

    Underlying macroeconomic factors:
    Papua New Guinea's economy is heavily dependent on natural resources, with mining and agriculture being the major contributors to the country's GDP. The country has been facing economic challenges in recent years due to the decline in commodity prices and the impact of the COVID-19 pandemic. These factors have a significant impact on the government's ability to invest in healthcare infrastructure and vaccine programs.In conclusion, the Vaccines market in Papua New Guinea is slowly developing due to the challenges posed by the country's geography, traditional beliefs, and economic situation. However, the increasing focus on healthcare infrastructure and the role of the private sector are expected to drive growth in the market in the coming years.

    Global Comparison

    Most recent update: Jun 2024

    Source: Statista Market Insights

    Methodology

    Data coverage:

    Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

    Modeling approach / Market size:

    Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

    Forecasts:

    In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

    Additional notes:

    Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

    Health

    Access more Market Insights on Health topics with our featured report

    Vaccines: market data & analysis - BackgroundVaccines: market data & analysis - Cover

    Key Market Indicators

    Notes: Based on data from IMF, World Bank, UN and Eurostat

    Most recent update: Sep 2024

    Source: Statista Market Insights

    Explore more high-quality data on related topic

    Coronavirus (COVID-19): vaccines and vaccination campaign

    As of March 2023, more than 13 billion COVID-19 vaccine doses had been administered worldwide. Wide-spread vaccine availability, increasing herd immunity, and lower case numbers led to renewed hope and a feeling of normality in 2023. However, especially during the winter seasons and with the potential emergence of new variants of the virus (like Omicron in 2021-2022), tracking of coronavirus cases repeatedly becomes a focus for the public. Thus, there is a level of uncertainty about what developments the winter season 2023/2024 might bring.
    More data on the topic

    Contact

    Get in touch with us. We are happy to help.